Furthermore, PRAME is significantly increased in diverse hematologic malignancies, including acute and chronic leukemias, non-Hodgkin’s lymphomas, and multiple myeloma, distinguishing it from the majority of other tumor-associated antigens (TAAs) (34–36, 43–46). Here, PRAME is linked to hematologic disorder.